Atlas Trials

Study to Assess Safety, Reactogenicity and Immunogenicity of the VACCINE RNA MCTI CIMATEC HDT (HDT-301) Vaccine Against COVID-19

Clinical trial NCT04844268 · UNKNOWN

Trial details

NCT number
NCT04844268
Sponsor
SENAI CIMATEC
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
SARS-CoV-2
Start date
2022-01-13
Primary completion
2022-09-01
Enrollment
90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.